These findings suggest that exogenous administration of CNP-53 may be able to restore craniofacial morphology and foramen magnum size in the patients whose SOS at the cranial base is still present as well as short stature in individuals with a growth disorder. Here, CNP is linked to hereditary endocrine growth disease.